Svelte Medical Systems, Inc. Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In-Man Study
5/23/2013 11:06:17 AM
More...
|
Svelte Medical Systems, Inc. Announces Treatment of First Patient in the DIRECT II Drug-Eluting Stent Study
1/30/2013 9:56:19 AM
More...
|
Svelte Medical Systems, Inc. Announces Treatment of First Patient in the ACES Effectiveness Study
12/20/2012 9:06:49 AM
More...
|
Svelte Medical Systems, Inc. Announces FDA Approval to Initiate a Pivotal Study of Its Coronary Stent Integrated Delivery System (IDS)
10/22/2012 9:36:59 AM
More...
|
Svelte Medical Systems, Inc. Taps Jack Darby as New President and CEO
10/10/2012 6:57:33 AM
More...
|
Svelte Medical Systems, Inc. Raises $8 Million
6/29/2012 8:53:33 AM
More...
|
Svelte Medical Systems, Inc. Announces Start of the FAASTER Post-Market Registry Study
6/14/2012 11:29:09 AM
More...
|
Svelte Medical Systems, Inc. Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
5/15/2012 10:43:29 AM
More...
|
Fischell Stent Development Co., Svelte Medical Systems, Inc., Raises $17 Million in Series B Round
12/19/2011 7:35:20 AM
More...
|
Svelte Medical Systems, Inc. Announces Treatment of First Patient in the DIRECT Drug-Eluting Stent Study
11/8/2011 9:09:43 AM
More...
|
|